吉林中医药2017，Vol.37Issue(6)：557-559,3.DOI:10.13463/j.cnki.jlzyy.2017.06.006
康艾注射液联合西药对失代偿期乙肝肝硬化患者肝功能改善及抗病毒疗效分析
Effect ofKangai injection combined with western medicine on hepatic function improvement and antiviral therapy in patients with hepatitis B liver cirrhosis
摘要
Abstract
Objective To investigate the antiviral effect ofKangai injection combined with entecavir on patients with decompensated hepatitis B cirrhosis and its effect on liver function.Methods 144 patients with decompensated hepatitis B liver cirrhosis were randomly divided into control group and treatment group, 72 cases in each group. Control group was treated with entecavir. Treatment group was treated withKangai injection combined with entecavir. The changes of liver function indexes, serum virological indexes and AFP levels were recorded before and after treatment, and the adverse reactions were recorded during treatment.Results The levels of ALT, AST, TBIL, HBeAg, HBV DNA, AFP and Child-Pugh in 2 groups were lower than those before treatment (P<0.01), and treatment group was lower than control group (P<0.05 orP<0.01). After treatment, the recovery rate of ALT, negative rate of HBeAg were higher than control group (P<0.05 orP<0.01), there was no significant difference in HBV DNA negative conversion rate and HBeAg seroconversion rate between 2 groups after treatment (P>0.05). There was no significant difference between 2 groups in mortality and causes of death (P>0.05). The incidence of adverse reactions in treatment group was lower than that in control group (P<0.05 orP<0.01).ConclusionKangai injection combined with entecavir can improve the liver function and serum virological indexes of patients with decompensated hepatitis B liver cirrhosis, and the antiviral efficacy is better than that of entecavir alone.关键词
失代偿期乙肝肝硬化/康艾注射液/恩替卡韦/肝功能Key words
hepatitis B liver cirrhosis/Kangai injection/entecavir/liver function分类
医药卫生引用本文复制引用
李艳萍..康艾注射液联合西药对失代偿期乙肝肝硬化患者肝功能改善及抗病毒疗效分析[J].吉林中医药,2017,37(6):557-559,3.基金项目
河南省医疗计划项目(20160312). （20160312）
